PET/CT with 68Gallium-DOTA-peptides in NET: An overview
Authors:
- Valentina AmbrosiniVAValentina Ambrosini
- Davide CampanaDCDavide Campana
- Domenico RubelloDRDomenico Rubello
- 1 November 2011
- journal article
- review article
- Published by Elsevier in European Journal of Radiology
- Vol. 80 (2) , e116-e119
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide ScintigraphyJournal of Nuclear Medicine, 2010
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM Classification based on recommendations of the IASLC Staging CommitteeHistopathology, 2009
- Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDGCancer, 2008
- Processing of Generator-Produced 68Ga for Medical ApplicationJournal of Nuclear Medicine, 2007
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursGut, 2005
- Epidemiology of Neuroendocrine TumoursNeuroendocrinology, 2004